Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06545097 · ClinicalTrials.gov registry record · Phase 3
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
A Phase 3 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 279
- Enrollment target
NCT06545097 is a Phase 3 study that has completed, run by Tris Pharma. The registered enrollment target is 279 participants.
The verdict
NCT06545097, a Phase 3 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 279 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.
Interventions
- DRUG Placebo
- DRUG Cebranopadol 400 ug
- DRUG Cebranopadol 200 ug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06545097
The ClinicalTrials.gov registry entry for NCT06545097 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tris Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06545097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06545097 about?
NCT06545097 is a clinical study titled "A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty". The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.
What is the current status of trial NCT06545097?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 279 participants. The study started on 2024-09-03. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT06545097?
The interventions under investigation include: Placebo (DRUG), Cebranopadol 400 ug (DRUG), Cebranopadol 200 ug (DRUG).
Who is sponsoring clinical trial NCT06545097?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.